Press release BoxID: 140237 (biolitec biomedical technology GmbH)
  • biolitec biomedical technology GmbH
  • Otto-Schott-Str. 15
  • 07745 Jena
  • Contact person
  • Ariane Oltmanns
  • +49 (3641) 5085-54

biolitec AG doubles EBIT to Euro 1.7 million

First quarter 2007/2008 revenue grows by 26 % to Euro 9.3 million, Laser revenue section growsby 60%

(PresseBox) (Jena, ) biolitec AG, Jena listed in the Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409)managed to increase the revenues during the first quarter 2007/2008 by 26 % to Euro 9.3 million (previous year: Euro 7.4 million). The gross profit amounted to Euro 6.6 million (previous year Euro 5.1 million)and the EBIT increased by 109% to Euro 1.7 million (previous year Euro 0.8 million). The operating profit increased by 65 % from Euro 1.1 million to Euro 1.8 million.

Due to the strong sales increase especially for the BPH treatment and aesthetic treatment methods (ELVeS™ etc.) net income increased to Euro 1.3 million (previous year Euro 0.79 million). Continuous high R&D investments of Euro 1.4 million, representing 15%of sales, ensure the groups long term growth and profitability.

The strongest increase with 60 % respectively 14 % were achieved in biolitec’s traditional business: lasers and fibres optic probes. Due to the strong growth in the USA the North American share of overall sales increased to 52% (last year 42 %).

biolitec AG expects for the current fiscal year further dynamic growth as well as an improved EBIT. The basis for this growth is strong demand for the companies BPH treatment in the US and favourable reimbursement codes in Germany as well as the company’s new ELVES™ Painless vein treatment and aesthetic therapies in general.